Exploiting research conducted at Kyoto Prefecture University of Medicine, Aurion Biotech is focusing on therapies that can restore vision.
Aurion Biotech, a US-based ophthalmology-focused regenerative therapies developer based on work at Kyoto Prefecture University of Medicine, obtained $120m in funding yesterday led by Deerfield Management.
Eye care products developer Alcon took part in the round, as did Petrichor Healthcare Capital Management, Flying L Partners, KKR-backed Falcon Vision and Visionary Ventures.
Aurion Biotech’s initial programme is a cell therapy aimed at corneal oedema secondary to endothelial dysfunction, a condition that leads to vision loss and can currently only be treated…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
